GlassScriptPhysician profile
Farzad Nowrouzzadeh
NPI 1730249848
$3,373.73
in general payments reported to CMS, 2019-2025
25 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $86.34 · 2021: $639 · 2022: $719 · 2023: $782 · 2024: $391 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497 · Consulting Fee: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.88 |
| Consulting Fee | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,856.76 | 2019-2025 | |
| Cook Medical LLC | $211.35 | 2019-2024 | Fusion, Saeed, Hemospray |
| Janssen Biotech, INC. | $183.30 | 2023-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $129.39 | 2023-2025 | Dupixent |
| Olympus America INC. | $127.33 | 2019-2025 | Endoclot Phs, Visiglide |
| Pfizer INC. | $102.21 | 2023-2024 | |
| Covidien LP | $99.15 | 2019 | |
| Echosens North America, INC. | $63.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.95 | 2020-2024 | Eohilia |
| Qol Medical, LLC | $59.03 | 2019-2021 | |
| Genzyme Corporation | $50.24 | 2023-2025 | |
| Boston Scientific Corporation | $50.00 | 2023 | |
| Intercept Pharmaceuticals, INC. | $44.20 | 2022-2025 | |
| Gilead Sciences, INC. | $40.74 | 2020-2022 | |
| Vivus LLC | $37.56 | 2021-2023 | Qsymia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.99 | 2024 | Xifaxan |
| Ferring Pharmaceuticals INC. | $33.91 | 2023 | Rebyota |
| Evoke Pharma, INC. | $30.75 | 2020 | |
| Madrigal Pharmaceuticals | $28.43 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $26.70 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $25.28 | 2021 | |
| Aimmune Therapeutics, INC. | $22.70 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $20.22 | 2021 | |
| Redhill Biopharma INC. | $19.89 | 2020 | |
| Merck Sharp & Dohme LLC | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzad Nowrouzzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.